Table 2.

ctDNA mutation detection kit.

Kit	Target	Cancers	Technology	Specificity	LoD	Company	Country
AVENIO ctDNA Expanded Kit	77 gene panel (including 192Kb, ABL1, AKT1, BRAF, and PIK3CA)	Lung cancer and colorectal cancer	Next-generation sequencing	>99%	0.10%	Roche	Switzerland
AVENIO ctDNA Target Kit	17 NCCN guideline-aligned genes (81 kb)	Lung cancer and colorectal cancer	Next-generation sequencing	>99%	0.10%	Roche	Switzerland
AVENIO ctDNA Surveillance Kit	17 NCCN guideline-aligned genes plus 471 frequently mutated, disease-associated regions across 197 genes	Lung cancer and colorectal cancer	Next-generation sequencing	>99%	0.10%	Roche	Switzerland
Super-ARMS® EGFR Mutation Detection Kit	Covers the 42 most frequent EGFR mutations	Non-small cell lung cancer	Real-time PCR	100%	0.20%	AmoyDx	China
OncoBEAM EGFR Kit V2 (RUO)	36 EGFR mutations of oncogene exons 18, 19, 20, and 21 (including T790M and C797S)	Non-small cell lung cancer	Highly sensitive BEAMing digital PCR technology	>90%	0.01%	Sysmex	Japan
Guardant360® CDx	Single nucleotide variants (SNVs) and insertions and deletions (indels) in 55 genes; copy number amplifications (CNAs) in 2 genes; fusions in 4 genes	Non-small cell lung cancer	Qualitative next-generation sequencing	100%	0.20%	Guardant Health	USA
FoundationOne® Liquid CDx	Substitutions and insertions and deletions (indels) in 311 genes, including rearrangements and copy number losses only in BRCA1 and BRCA2	Non-small cell lung cancer and prostate cancer	Qualitative next-generation sequencing	100%	0.40%	Foundation Medicine	USA
Guardant Reveal™	Not published	Early-stage colorectal, breast, and lung cancers	Next-generation sequencing	100%	0.01%	Guardant Health	USA